In a report released today, Joseph Thome from TD Cowen maintained a Buy rating on Alkermes (ALKS – Research Report), with a price target of $35.00. The company’s shares closed yesterday at $30.08.

Stifel has upgraded Alkermes (NASDAQ:ALKS) to buy from hold, citing increased confidence in the company’s narcolepsy drug ...

Alkermes (NASDAQ:ALKS – Get Free Report) had its target price dropped by equities researchers at The Goldman Sachs Group from ...

During the last three months, 9 analysts shared their evaluations of Alkermes ALKS, revealing diverse outlooks from bullish to bearish. The table below provides a concise overview of recent ...

Fintel reports that on November 5, 2024, Stifel upgraded their outlook for Alkermes (NasdaqGS:ALKS) from Hold to Buy. Analyst ...

Alkermes (NASDAQ:ALKS – Free Report) had its price target lowered by Cantor Fitzgerald from $48.00 to $43.00 in a research ...

Analyst Douglas Tsao from H.C. Wainwright reiterated a Hold rating on Alkermes (ALKS – Research Report) and keeping the price target at ...

Alkermes is a biopharmaceutical company primarily involved in developing treatments for central nervous system disorders. Its current lineup includes schizophrenia treatment Aristada ...

Cantor Fitzgerald lowered the firm’s price target on Alkermes (ALKS) to $43 from $48 and keeps an Overweight rating on the shares. Alkermes reported Q3 revenues below consensus estimates but in ...

Alkermes (NASDAQ:ALKS) is gearing up to announce its quarterly earnings on Thursday, 2024-10-24. Here's a quick overview of what investors should know before the release. Analysts are estimating ...

Stifel has upgraded Alkermes (NASDAQ:ALKS) to buy from hold, citing increased confidence in the company’s narcolepsy drug candidate ALKS2680. The investment bank said it is now “very confident ...